Skip to content

Study · Other design · 2022

2 results

Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.

Danila GM, Puiu M, Zamfir LG, Bala C

Talanta29 Sept 2021Cited by 4 (Europe PMC)

PMID34736642 (opens in a new tab)DOI10.1016/j.talanta.2021.122905 (opens in a new tab)PepBankPUB-34736642
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabOther designActivity measurement

    In competitive assays with labelled ghrelin, synthetic ghrelin mimetics such as CJC‑1295 acted rather as competitive inhibitors of the ghrelin and GHS-R1a interaction, unlike the cannabinoids that promoted it.

    In plain wordsIn lab tests, ghrelin mimics such as CJC‑1295 acted more like blockers of ghrelin binding to its receptor, while cannabinoids made this binding stronger.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    DecreaseEffect on ghrelin and GHS-R1a interaction
    Study

    n: not reported in source

    GHS-R1a competitive assays with labelled ghrelin
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The affinity profiles of CBD and carboxy-THC are significantly different from the profiles of synthetic GHR mimetics such as CJC-1295 or [D-Arg1-D-Phe5-D-Trp7,9-Leu11]-Substance P peptides, which are the most common interferents; the cannabinoids promoted…

Studies that did not test the peptide alone1

In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking CJC-1295 (with DAC).

  1. 02LabNot a test of CJC-1295 (with DAC) aloneOther designOther

    Ghrelin mimetics, a class that includes CJC‑1295, caused no interference in the cannabinoid urine assay at concentrations up to 100 ng/mL.

    In plain wordsIn lab tests, CJC‑1295 and similar ghrelin mimics did not disturb the urine test for cannabinoids at the tested levels.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    No significant changeInterference with the cannabinoid urine assay
    Study

    n: not reported in source

    GHS-R1a competitive assays with labelled ghrelin
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    whereas GHR mimetics display no interference at concentrations up to 100 ng/mL
    1 context sentence
    Summary · context
    synthetic GHR mimetics such as CJC-1295 or [D-Arg1-D-Phe5-D-Trp7,9-Leu11]-Substance P peptides, which are the most common interferents

    In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.